[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mixed-urinary-incontinence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mixed-urinary-incontinence":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,74,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100552987","trial-of-transurethral-bulking-agent-injection-versus-single-incision-sling-for-stress-urinary-incontinence-100552987",false,"NCT06480227","Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence","A Randomized Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence","BASIS","Inclusion Criteria:\n\n* Women ≥ 21 years\n* For \\> 3 months, bothersome SUI (response of somewhat, moderately, or quite a bit) without UUI or stress-predominant MUI. For those with equal bother of UUI and SUI, clinician determination that SUI is more severe\u002Fsignificant than UUI is required.\n* A positive cough stress test on standardized non-invasive testing or urodynamic SUI within the past 18 months.\n* Normal PVR \\\u003C 150 mL\n* Candidate for either study procedure as determined by treating surgeon\n* Available for up to 3 years.\n* Agrees to randomization.\n\nExclusion Criteria:\n\n* Anterior\u002Fapical vaginal prolapse beyond the hymen (\\>0 on POPQ)\n* Urge-predominant mixed UI despite stable therapy\n* Advanced UUI\u002FOAB 3rd line therapy treatment within 1 year of enrollment.\n* Planned hysterectomy, urethral or anterior\u002Fapical surgeries s requiring general anesthesia at the time of SUI treatment, during the last 6 months, or planned within the next 12 months.\n* Malignancy or history of radiation of the pelvis\n* Pregnant, post-partum, breast feeding or plans for pregnancy within 1 year\n* Incomplete emptying (PVR \\> 150mL)\n* Prior anti-incontinence procedure\n* Neurogenic bladder\n* Unwilling to continue current UUI treatment until completion of primary outcome at 12 months\n* Prior adverse reaction to synthetic mesh or urethral bulking material\n* Chronic bladder or pelvic pain conditions (e.g., Interstitial cystitis, painful bladder syndrome, fibromyalgia, chronic pelvic pain, etc.)\n* Active treatment for SUI with a pessary. For those using a pessary or other SUI support device, a 3-week washout period should occur prior to assessing baseline measures.","FEMALE","21 Years",{"count":20,"type":21},358,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a multicentered, double-blind, randomized controlled, surgical trial of 358 women with inadequate symptom relief of stress urinary incontinence (SUI) or stress predominant mixed urinary incontinence (MUI) after conservative care.\n\nThe Primary Aim is to determine the comparative effectiveness (as defined by \"much\" or \"very much\" better on PGI-I) of transurethral bulking agent (TBA) \\[for 1 or 2 injections in 12 months\\] vs. single-incision sling (SIS) 12 months after treatment intervention in women with predominant stress urinary incontinence (SUI).",[27,28,29],"Stress Urinary Incontinence","Urinary Incontinence","Mixed Urinary Incontinence",[28,31,32,33],"Pelvic Floor Disorders","Single Incision Sling","Transurethral Bulking Agent","RECRUITING","2026-06-04",{"date":37,"type":38},"2026-06-08","ACTUAL",{"date":40,"type":38},"2024-08-28",{"date":42,"type":21},"2030-12-31",{"name":44,"class":45},"NICHD Pelvic Floor Disorders Network","NETWORK",7,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":46},"100584176","augmenting-urinary-reflex-activity-study-4-including-extended-indications-100584176","NCT06885931","Augmenting Urinary Reflex Activity Study 4 (Including eXtended Indications)","Exploratory Safety and Feasibility Study of Personalized Adaptive Pudendal Neuromodulation for Mixed Urinary Incontinence and Extended Indications Using an Implanted (Picostim IITM) System","AURA-4X","Inclusion Criteria:\n\n* Female. NB: the definition of female refers to sex at birth.\n* Adult: aged ≥ 22 years (at the time of informed consent signature).\n* Patient self-reports both stress and urge episodes (clinician-opinion on history taking).\n* Patient has failed to respond to or could not tolerate conservative treatment as determined by the treating health care provider.\n* Duration of urinary incontinence symptom ≥ 6 months prior to the screening baseline visit date.\n* Able and willing to voluntarily sign informed consent form.\n* Able to participate in all testing and follow-up clinic visits associated with study protocol.\n* Patient is mobile and able to use a toilet.\n* In the opinion of the Investigator, the patient is capable of independently using the system components (after training).\n\nExclusion Criteria:\n\n* Patient is pregnant, breastfeeding, or plans to become pregnant at any time in the future.\n* Patient is unwilling or unable to use contraception during sexual intercourse for the duration of the study.\n* In the event that patient becomes pregnant during or after the study, they are not prepared to inactivate device for the whole period of the pregnancy.\n* Any significant medical condition that, in the opinion of the Investigator, is likely to interfere with study procedures, device operation, or likely to confound evaluation of study endpoints.\n* History of major psychiatric or personality disorder.\n* Any neurological condition that in the opinion of the investigator may interfere with normal bladder function (e.g., stroke, multiple sclerosis, Parkinson's disease, clinically significant peripheral neuropathy, or complete spinal cord injury).\n* Uncontrolled type I or type II diabetes (as defined by their routine care clinician or HBA1C ≥ 7.0).\n* History of cancer within 5 years prior to enrolment, except for a cancer that was determined to be free of systemic cancer risk, such as basal cell carcinoma.\n* Patient is taking antiplatelet and\u002For anticoagulant drugs including warfarin or newer alternatives (e.g., rivaroxaban, apixaban, dabigatran, edoxaban) which cannot be paused prior to surgery, or has a bleeding disorder that cannot be corrected prior to surgery.\n* Any clinical reason that, in the opinion of the Investigator, may compromise patient's safety during the study.\n* Currently participating in another interventional study. This excepts purely observational studies, e.g., registries.\n* Patient participation in vigorous physical activities where these cannot be restricted for a period of 6 weeks post-implantation.\n* Patient unwilling to stop any future participation in scuba diving below 10m. BMI ≥ 40kg\u002Fm2 or waist circumference \\> 127cm\n* Documented history of allergic response to titanium, zirconia, polyurethane, epoxy, or silicone.\n* Skin, orthopedic or neurological anatomical limitations at the site of implant that could prevent successful placement of an electrode or IPG. This includes active perineal sepsis or perianal sepsis (e.g., anal fistula and pilonidal sinus).\n* Knowledge of planned MRIs, diathermy, medical microwave exposure, high output ultrasonic exposure, or medical RF energy exposure.\n* Implantable neurostimulator or antennae, pacemaker or defibrillator in-situ (anywhere in body).\n\nExclusion Criteria (Urological):\n\n* Known diagnosis of interstitial cystitis or bladder pain syndrome as defined by either AUA or EAU guidelines. Diagnosis of any other chronic pelvic or regional pain syndrome\n* Documented bladder emptying syndrome including neurogenic bladder.\n* Known abnormal post void residual (\\> 100 ml).\n* Any prolapse (symptomatic or asymptomatic) currently at or below the hymenal level Known urinary tract mechanical obstruction such as urethral stricture and\u002For bladder neck contracture.\n* Current symptomatic urinary tract infection (UTI) or more than 3 culture-proven UTIs in past year.\n* Current diagnosis of vesicoureteral reflux\n* Current diagnosis of bladder stones\n* History of bladder tumour (benign or malignant) -Suspected or proven pudendal nerve entrapment syndrome. In patients with co- existent chronic pelvic pain and urinary incontinence symptoms, Nantes criteria will be used for screening. Patients meeting essential criteria will be excluded from the study.\n* Suspected or proven severe pudendal nerve damage at discretion of clinician with or without specialist investigations\n* Any previous experience of pudendal nerve stimulation using an implanted lead.\n* Previous failure of SNM therapy (based on implantation; failed test phase is not an exclusion)\n* Major previous urethral or bladder surgery (excisional or reconstructive) at discretion of investigator\n* SUI surgery e.g. urethral slings, tapes, and bulking agents colposuspension within last 2 years; \\> 2 years at discretion of investigator\n* Prolapse surgery e.g. colposuspension \u002F colporrhaphy within last 12 months with current confirmation via pelvic exam of no recurrence \\> or = to Stage 2 pelvic organ prolapse\n* Previous use of bladder botox injections within last 6 months","22 Years",{"count":57,"type":21},86,[24],"Exploratory safety and feasibility study of personalized adaptive pudendal neuromodulation for mixed urinary incontinence and extended indications using an implanted (Picostim™ II) system.",[29,61,62,63],"Stress Urinary Incontinence (SUI)","Chronic Pelvic Pain","Urge Urinary Incontinence","2026-05-13",{"date":66,"type":38},"2026-05-15",{"date":68,"type":38},"2025-06-24",{"date":70,"type":21},"2030-01",{"name":72,"class":73},"Amber Therapeutics Ltd","INDUSTRY",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100636333","implantation-of-an-adjustable-suburethral-sling-is-an-effective-treatment-method-for-patients-with-mixed-urinary-incontinence-of-moderate-to-severe-severity-after-which-the-severity-of-the-stress-and-urgency-components-is-reduced-100636333","NCT07564323","Implantation of an Adjustable Suburethral Sling is an Effective Treatment Method for Patients With Mixed Urinary Incontinence of Moderate to Severe Severity, After Which the Severity of the Stress and Urgency Components is Reduced.","Optimizing the Management of Patients With Mixed Urinary Incontinence.","Inclusion Criteria:\n\n* Women over 18 years of age.\n* Mixed urinary incontinence (stress and urgency components, with the stress component being predominant or equal) of moderate to severe severity, confirmed by questionnaire data.\n* Signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Isolated stress or urge urinary incontinence.\n* Contraindications to diagnosis and treatment.\n* Obstructive urination, large residual urine volume.\n* Chronic pelvic pain syndrome.\n* Pelvic organ prolapse (grade 2 or higher according to POP-Q).\n* History of any suburethral sling implantation.\n* History of surgical treatment for pelvic organ prolapse.\n* Pregnancy.","18 Years",{"count":83,"type":21},156,[24],"The aim of this clinical study is to optimize treatment outcomes in patients with mixed forms of urinary incontinence by implanting an adjustable suburethral sling and to determine factors influencing treatment effectiveness. The main questions it aims to answer are:\n\n1. What is the effectiveness of an adjustable suburethral sling in patients with mixed urinary incontinence?\n2. How do preoperative medications and other factors affect the effectiveness of adjustable suburethral sling implantation?\n3. How does quality of life change in these patients after surgery? Participants will undergo implantation of an adjustable suburethral sling. Postoperatively, the effectiveness of the sling for mixed urinary incontinence will be assessed. Predictors of treatment effectiveness will also be identified.\n\nPatients will be examined 24 hours after surgery, 2 months later, and 1 year later.",[29],[88],"mixed urinary incontinence, adjustable suburethral sling","NOT_YET_RECRUITING","2026-04-26",{"date":92,"type":38},"2026-05-04",{"date":94,"type":21},"2026-04-24",{"date":96,"type":21},"2028-04-24",{"name":98,"class":99},"Saint Petersburg State University, Russia","OTHER",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":119,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100609041","detrusor-nerve-radiofrequency-ablation-for-overactive-bladder-in-women-100609041","NCT07209397","Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women","A Randomized, Prospective, Multicenter, Double-Blind, Sham-Controlled Study to Assess the MORPHEUSV Radiofrequency (RF) Device in the Treatment of Female Patients With Idiopathic Overactive Bladder (OAB) With Urge Incontinence and\u002For Urge-Predominant Mixed Incontinence","DENARA","INCLUSION CRITERIA:\n\n* Female, aged 22 to 80 years inclusive at the time of consent.\n* History of idiopathic overactive bladder (OAB) symptoms for ≥6 months.\n* At least 7 episodes of urge urinary incontinence (UUI) over 3 days, as recorded in a 3-day bladder diary during screening.\n* Urge-predominant incontinence, defined as greater number of UUI episodes than stress urinary incontinence (SUI) episodes during screening.\n* Willing and able to complete the 3-day bladder diary.\n* Willing to discontinue OAB medications (e.g., anticholinergics, beta-3 agonists) at least 2 weeks prior to baseline treatment visit, if currently taking such medications.\n* Willing to use a reliable method of contraception during the study period, if of childbearing potential and sexually active.\n* Negative pregnancy test at screening (if applicable).\n* Willing and able to provide written informed consent and comply with study procedures and follow-up schedule.\n\nEXCLUSION CRITERIA:\n\n* Predominant stress urinary incontinence (SUI) based on bladder diary\n* Currently pregnant, breastfeeding, or planning pregnancy during the study\n* History of neurologic conditions affecting bladder function (e.g., multiple sclerosis, spinal cord injury, Parkinson's disease)\n* Active urinary tract infection (UTI) at screening\n* History of interstitial cystitis, bladder pain syndrome, or chronic pelvic pain\n* Prior or current bladder cancer, pelvic malignancy, or pelvic radiation\n* Pelvic organ prolapse beyond the hymen (POP-Q stage \\> II)\n* Implanted neuromodulation device or prior sacral nerve stimulation\n* Use of bulking agents, Botox, or surgical treatment for incontinence within 12 months\n* Prior pelvic floor RF treatment or laser vaginal rejuvenation\n* Significant pelvic anatomical abnormalities that interfere with treatment\n* Use of investigational drug or device within 30 days before screening\n* Any condition that, in the investigator's opinion, would interfere with safe study participation or data integrity\n* Uncontrolled systemic disease (e.g., uncontrolled diabetes, cardiovascular disease)\n* Inability or unwillingness to comply with study requirements or follow-up","80 Years",{"count":110,"type":21},202,[24],"The goal of this clinical trial is to learn if a vaginal radiofrequency (RF) device called MORPHEUSV works to treat overactive bladder (OAB) in women. Researchers also want to learn how safe the device is for this indication. This study will include women ages 22 to 80 who have had OAB symptoms for at least 6 months. The main questions it aims to answer are: Does the MORPHEUSV device lower the number of daily episodes of accidental urine leakage caused by urgency? Does it work better than a sham (placebo) treatment? Researchers will compare the MORPHEUSV device to a sham treatment to see how well it reduces symptoms of overactive bladder. Participants will: 1) Receive one session of either the MORPHEUSV or sham treatment. 2) Track their symptoms using a diary and questionnaires 3) Return for three to six follow-up visits over 12 months. This study is being conducted at multiple clinics in the United States.",[114,115,63,116,29,117,118],"Overactive Bladder","Overactive Bladder (OAB)","Mixed Urinary Incontinence (Urge-Predominant)","Idiopathic Overactive Bladder With Urinary Incontinence","Idiopathic Overactive Bladder",[120,121,122,123,124,125],"Overactive bladder","Urge urinary incontinence","Mixed urinary incontinence","Female urinary symptoms","urogynecology","Female Urology","2026-01-28",{"date":128,"type":38},"2026-01-30",{"date":130,"type":38},"2025-11-25",{"date":132,"type":21},"2027-11-30",{"name":134,"class":73},"InMode MD Ltd.",9]